Lb Pharmaceuticals reported net income of -$51.60M for the quarter ended Jun 2026. This income statement covers 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.36M | 0.36M | 0.36M | 0.36M | 5.81M | 8.05M | 28.67M | 28.68M |
| Operating items | ||||||||
| Research & DevelopmentR&D | 10.66M | 0.38M | 3.42M | 2.42M | 2.42M | 8.48M | 14.64M | 44.15M |
| Selling, General & AdministrativeSG&A | 5.42M | 5.16M | 3.01M | 2.44M | 2.83M | 5.39M | 7.46M | 9.77M |
| Operating ExpensesOpex | 16.08M | 5.54M | 6.43M | 4.86M | 5.25M | 13.87M | 22.10M | 53.91M |
| EBIT | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Non-operating items | ||||||||
| Non Operating Investment Income | 0.50M | 0.36M | 0.12M | |||||
| Interest & Investment IncomeInt & Inv Inc | 0.38M | 0.30M | 0.24M | 0.18M | 0.71M | 2.80M | 2.85M | 2.97M |
| Non Operating IncomeNon Op. Inc. | 1.90M | 0.47M | 1.12M | -0.01M | 1.69M | 2.40M | 3.05M | 2.31M |
| Net income details | ||||||||
| EBT | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Tax ProvisionsTaxes | 0.00M | 0.00M | ||||||
| Profit After TaxPAT | -14.18M | -5.07M | -5.31M | -4.87M | -3.60M | -11.47M | -19.05M | -51.60M |
| Income from Continuing OperationsIncome (Continuing) | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Consolidated Net IncomeConsol Net Inc. | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Income towards Parent CompanyParent Net Inc | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Net Income towards Common StockholdersNet Income | -14.18M | 57.97M | -5.31M | -4.87M | -3.56M | 13.71M | -19.05M | -51.60M |
| Additional items | ||||||||
| EPS (Basic) | -39.49 | 161.82 | -14.79 | -13.58 | -0.61 | 1.70 | -0.67 | -1.71 |
| EPS (Diluted) | -39.49 | 161.82 | -14.79 | -13.58 | -0.61 | 1.70 | -0.67 | -1.71 |
| Shares Outstanding | 0.36M | 0.36M | 0.36M | 0.36M | 5.81M | 8.05M | 28.24M | 30.14M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.36M | 0.36M | 0.36M | 0.36M | 5.81M | 8.05M | 28.24M | 30.14M |
| EBITDA | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Tax Rate | -0.02 | -0.01 |